This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Anuh Pharma Limited has informed the Exchange regarding 'Intimation Pursuant To Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma Limited reported FY2026 audited results with revenue from operations growing 16.6% year-on-year to Rs. 77,166 lakhs. However, profit after tax declined 13.3% to Rs. 4,105 lakhs compared to Rs. 4,735 lakhs in FY2025. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The Board recommended a dividend of Rs. 1.50 per share (30% payout), subject to shareholder approval at the AGM on August 12, 2026. The company received requests from 9 promoter group shareholders holding approximately 9.5 lakh shares (0.95%) seeking re-classification from 'Promoter Group' to 'Public' category under Regulation 31A. The statutory auditor issued an unmodified opinion, confirming clean financials. Operating cash flow turned negative at Rs. 301 lakhs primarily due to a significant increase in inventories (up Rs. 7,327 lakhs). A 1:1 bonus issue was completed in July 2025.
Revenue growth of 16.6% was offset by margin compression and PAT decline, resulting in lower profitability year-on-year. The negative operating cashflow and inventory build-up warrant monitoring. Promoter re-classification requests are minor (under 1%) but signal potential further changes in shareholding structure. Dividend payout remains modest at 30%.
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹202.1 Cr | ₹198.1 Cr | +2.0% |
| Operating profit | ₹16.77 Cr | ₹15.88 Cr | +5.6% |
| Profit after tax | ₹11.68 Cr | ₹12.46 Cr | −6.2% |
| EBITDA margin | 9.8% | 9.4% | +0.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.